secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001193125-25-119408
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kalaris Q1 net loss $10.2M ($2.52/shr); cash $101M; TH103 Phase 1 data expected Q4 2025
--------------------------------------------------------------------------------

- Net loss of $10.2M for Q1 2025 vs $3.4M for Q1 2024; diluted EPS loss $2.52.
- Cash and equivalents $101.0M as of March 31, 2025, expected to fund operations into Q4 2026.
- R&D expenses $6.0M (up from $2.0M YoY) driven by TH103 Phase 1 trial initiation.
- Phase 1 trial of TH103 for nAMD actively enrolling; initial clinical data expected Q4 2025.
- Completed merger with AlloVir in March 2025; appointed Leone Patterson to Board and Audit Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525119408/0001193125-25-119408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312525119408/d916904d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-119408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer